In The News
This page contains articles written by persons not affiliated with vTv Therapeutics. The views expressed in the articles are those of the author and do not reflect the views of the company. vTv Therapeutics disavows any obligation to update or correct the information contained in these articles.
Hypoglycemia in Type 1 Diabetes: Near term challenges, long-term risks, and the need for new therapeutics options
Carmen Valcarce, Executive Vice President and Chief Scientific Officer of vTv Therapeutics discusses the complex issues surrounding the treatment of type 1 diabetes, looking in particular at hypoglycemia and the impact it has both on patients and researchers.
Read More
This article is taken from Pharmafile Spring 2021, pages 39-41 © Samedan Ltd
Realize the Potential of Adjunctive Therapy in the Treatment of Type 1 Diabetes
One approach to improve care and clinical outcomes for people with type 1 diabetes involves the use of adjunctive therapies along with insulin to improve glucose control or enable reductions in insulin doses.
Read More
VTV Celebrates a Double Positive
Yesterday’s clinical study success has underlined VTV’s status as a small-cap bet on Alzheibetes.
Read More